ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,615.35
0.55%
US Tech 100
19,804.00
0.64%
Dow Jones
40,000.90
0.62%
Brent Oil
84.57
0.00%
Bitcoin
60,190.91
1.62%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Sage Therapeutics Inc (SAGE) Quote

Sage Therapeutics Inc

Sage Therapeutics Inc (SAGE)

Sage Potash Corp
11.76
0.025
(0.21%)
Closed July 14 4:00PM
Delayed by 15 minutes
11.76
0.00
(0.00%)
After Hours: 6:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
11.76
Bid
9.71
Ask
12.43
Volume
829,251
11.52 Day's Range 11.9899
9.76 52 Week Range 49.74
Market Cap
706.236M
Previous Close
11.735
Open
11.77
Last Trade
204352
@
11.76
(average)
Last Trade Time
Financial Volume
$ 9,711,537
VWAP
11.7112
Average Volume (3m)
1,230,996
Shares Outstanding
60,182,031
Dividend Yield
-
PE Ratio
-1.31
Earnings Per Share (EPS)
-9
Revenue
86.46M
Net Profit
-541.49M

About Sage Therapeutics Inc

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical tri... Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.sagerx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Sage Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SAGE. The last closing price for Sage Therapeutics was $11.74. Over the last year, Sage Therapeutics shares have traded in a share price range of $ 9.76 to $ 49.74.

Sage Therapeutics currently has 60,182,031 shares outstanding. The market capitalization of Sage Therapeutics is $706.24 million. Sage Therapeutics has a price to earnings ratio (PE ratio) of -1.31.

Sage Therapeutics (SAGE) Options Flow Summary

SAGE Options Flow

Overall Flow

Bullish

Net Premium

247k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

SAGE Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 11 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 11 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 11 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 11 2024
Edgar (US Regulatory)

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease

The SURVEYOR Study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between...

June 11 2024
Business Wire

Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside...

June 05 2024
Business Wire

Sage Therapeutics to Participate in Upcoming May Investor Conferences

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following...

May 07 2024
Business Wire

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for...

April 25 2024
Business Wire

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

- In the Phase 2 PRECEDENT Study, dalzanemdor (SAGE-718) did not show statistically significant differences versus placebo on the primary endpoint in patients with mild cognitive impairment in...

April 17 2024
Business Wire

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April...

April 11 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.1410.734463276810.6212.0610.376946211.22598572CS
40.363.1578947368411.412.1410.22113683011.12099598CS
12-1.17-9.0487238979112.9314.979.76123099611.75568386CS
26-15.65-57.095950383127.4128.269.76109551416.28125701CS
52-37.87-76.304654442949.6349.749.76120850319.77811429CS
156-43.1-78.563616478354.8659.999.7679339230.06978601CS
260-178.94-93.833245936190.7193.569.7678843544.75209225CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.65M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

SAGE Discussion

View Posts
Monksdream Monksdream 3 months ago
SAGE over $10
👍️0
everton44 everton44 11 months ago
SAGE going to 36 dollars, every article and financial companies downgrading SAGE yet it goes up big. HAHAHA
👍️0
gail gail 11 months ago
i dont know anything about…

…

shorting. i am a simpleton, lol, i just trade like a normal trader.

not in this one, but made a bundle on my last few trades, including ttoo today. weeee!!
👍️0
everton44 everton44 11 months ago
we are all short selling the piss out of this now, come on board
👍️0
gail gail 11 months ago
so, they got approved yet…

..

it dropped huge today? im not in it but watching.
👍️0
AGORDON AGORDON 11 months ago
FDA approved Zuranolone for PPD. CRL for Major Depressive.
👍️0
AGORDON AGORDON 11 months ago
The FDA is still considering whether to approve zuranolone for clinical depression in addition to postpartum depression, but did not issue a decision on that indication.
👍️0
budgetthis budgetthis 2 years ago
I was gonna burn some SAGE today, in a therapeutic manner, like they do on Yellowstone to ward off evil spirits.

But no need……elevators going up today……lol.

$$ SAGE $$
👍️0
CjMitts CjMitts 3 years ago
Called the pump, How'd I know, garbby 10q report, RSI divergence. will be loading this at the bottom though with the money I make from this short, the potential of this companies pipeline is enormous.
👍️0
CjMitts CjMitts 3 years ago
Boom
👍️0
CjMitts CjMitts 3 years ago
Dont be fooled by the pump. Will be loading between 34-26. Surprised there's no talk on this page regarding the potential of this companies pipeline.
👍️0
thumper1 thumper1 4 years ago
im out high 68.eom
👍️0
thumper1 thumper1 4 years ago
bought 67.11. we will see
👍️0
NYCPuglet NYCPuglet 4 years ago
Sold at 77. Thank god. Lol.
👍️0
NYCPuglet NYCPuglet 5 years ago
In 1000 @ at 73. Easy profit flipper here. Very big whales behind this company.
👍️0
Daysinn4610 Daysinn4610 5 years ago
Ceo cfo cso all buying shares https://www.gurufocus.com/news/999044/sage-therapeutics-inc-sage-president--ceo-jeffrey-m-jonas-bought-481500-of-shares
👍️0
Daysinn4610 Daysinn4610 5 years ago
Some sage news https://www.streetinsider.com/dr/news.php?id=16261148
👍️0
keekee keekee 5 years ago
Lol....brig6and early. Crossing $80 today? The $125 may actually happen by the end if the month? We will see.
👍️0
keekee keekee 5 years ago
Seen this...though it is going to be just a few days apart. Congrats to BULLS....and I sure hope those that jumped in to short because I highlighted the stock GO BANKRUPT!!!
👍️0
keekee keekee 5 years ago
$74 now. Everyone that shorted past week is now in red. And it will get even more painful going forward. Sorry, losers!
👍️0
keekee keekee 5 years ago
$3 to $4 a day is fine for now. In a week or so we wi6see doing more than that number as we race back towards $125. When I saw BUY...and some.fools sell, all I think of is, Who the hell is their father!!!! Who do they get information from...David Einhorn or who? He just did 34% loss last year and is on track to be smothered again with the TSLA outperformance. We are headed up....Intelsat, SAGE, ASLN, FRAN, And a host of others.
👍️0
keekee keekee 5 years ago
We're headed to $80 very likely today. It's a one way train here m.j till.$100.
👍️0
Biobonic Biobonic 5 years ago
Post-hoc analysis revealed that in the MOUNTAIN Study, approximately 9% of patients in the SAGE-217 30 mg group had no measurable drug concentration, consistent with non-compliance in taking SAGE-217

In the 30mg group, 192 received the medication at the onset of the trial.

9% would approximate: 17 participants.

The trial had 28 participants withdraw by day 42. (14%) a significant number, especially since there was a good measure of efficacy.



👍️0
RJ Trotts RJ Trotts 5 years ago
I got out with 4.50 per share profit, we are both happy, enjoy your weekend. Hoping to find more winners next week.
👍️0
Nebuchadnezzar Nebuchadnezzar 5 years ago
Caught this falling knife yesterday, out up $6.45 profit
👍️0
keekee keekee 5 years ago
Watch when this stock went down from $68 yestersay. That was when I intentionally posted that I loaded. They came.and brought the it down. I reloaded. And they sre still here. Ditto for PTGX, 1, PRTY, AIHS, ASLN, AFH, SLDB, AFI, CBAY, ATIS. and a couple more. The have shorted most of these floats over 100% but still.manages tonhang on because folks have no idea that these stocks will fly double or triple. But check those out and good luck. They are mostly DOUBLERS in a month or two.
👍️0
keekee keekee 5 years ago
There are folks that short anything I buy. They are the idiots holding this down. CV lick on my name to see other stocks we play opposite. They have money but no brain. Investor money. They will shi ort anything I posted that I bought under any circumstance. They are the knes here. Ignote the selling and load. This will fly!!!
👍️0
T695 T695 5 years ago
I think we at resistance in the $66 are. The entire market will be over bought in a minute and this will sell off hard
👍️0
keekee keekee 5 years ago
Minimum close today will be $70. I will take that..from $54 and lower entry yesterday. This one is as easy...easy. will likely be trending toward $100 by month end
👍️0
T695 T695 5 years ago
Looks like my first outlook was the right one
👍️0
VictorMasonIsRight VictorMasonIsRight 5 years ago
SAGE test compromised by 9 non compliant patients?
Otherwise would have met all benchmarks?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152647122
👍️0
RJ Trotts RJ Trotts 5 years ago
up in pre-market right now, here's to hoping it bounces nicely
👍️0
T695 T695 5 years ago
On second thoughts, might me another 20% or so haircut today after all the downgrades
👍️0
T695 T695 5 years ago
It’s way over sold, but still could fall to 50ish
👍️0
T695 T695 5 years ago
I’m thinking we get a bounce from here to $66-67ish, when if it hits there it may either run back to low 70’s or pull back to 50’s then run to $70’s.... either way I see lows 50’s and lows 70’s as short term bottom and top
👍️0
RJ Trotts RJ Trotts 5 years ago
May add some here after hours, and see if it will bounce tomorrow. Best to all here. Hoping it is oversold!
👍️0
keekee keekee 5 years ago
Unfortunately, I brought them over..I mean the heavy sellers. These guys are blind in their rabid quest to trade against me. But I create losses for them. That is my mission now. We will see $100. The clueless sellers know it too!
👍️0
keekee keekee 5 years ago
Will cross $80 tom8. Must $100 by next week. The fools selling are misguided
👍️0
T695 T695 5 years ago
Might see by EOD
👍️0
keekee keekee 5 years ago
This thing may actually return to $1.25 by year end. That would be over 200% for.me. lol. In at $54 and lower..pre.
👍️0
keekee keekee 5 years ago
Loaded premkt at $53. Must get $100. Drug did not fail if you factor in the 9 candidates that did not take it. $100..let's go
👍️0
T695 T695 5 years ago
Make take a nibble at $50
👍️0
altruism altruism 5 years ago
4 according to 1 news source I saw
👍️0
Awl416 Awl416 5 years ago
How many billions that she’s off the market cap - wow
👍️0
NYCPuglet NYCPuglet 5 years ago
Such an easy predictable stock.
👍️0
cvm101 cvm101 5 years ago
So this Leerink Swann call of 1/7 is looking pretty idiotic now as stock crosses $144.00
Earlier they had downgraded and lowered target price to $80.00

Sage Therapeutics stock price target raised to $90 from $80 at Leerink
👍️0
NYCPuglet NYCPuglet 6 years ago
Once again it drops. Gotta love this flipper.
👍️0
NYCPuglet NYCPuglet 6 years ago
Wish I had funds last week to throw in. I sensed a big pop was coming.
👍️0
cvm101 cvm101 6 years ago
Well it has been - but with the approval to market the new drug its less a speculation and more an investable company. Longer term its worth $200. Most analyst target prices are in that area.
👍️0
NYCPuglet NYCPuglet 6 years ago
Yep. This is an insane flipper stock.
👍️0

Your Recent History

NASDAQ
SAGE
Sage Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved